Freedom biosciences emerges from stealth with $10.5 million seed financing to develop next-generation ketamine and psychedelic-based mental health treatments

San francisco--(business wire)--freedom biosciences, a clinical-stage biotechnology platform developing next-generation viable and efficacious ketamine and psychedelic therapeutics, today emerged from stealth with $10.5 million in seed financing. mbx capital led the round and was joined by psymed ventures, village global and the yale startup, among others. the new financing will help the company advance its current lead ketamine program as well as further multiple additional exploratory program
BHVN Ratings Summary
BHVN Quant Ranking